deltatrials
Not Yet Recruiting NA INTERVENTIONAL 2-arm NCT06421454

Clinical Trial for the Evaluation of Melatonin in the Treatment of Pressure Ulcers

Sponsor: Fundacion Rioja Salud

Conditions Pressure Ulcer
Updated 4 times since 2024 Last updated: May 14, 2024 Started: Sep 1, 2024 Primary completion: Jun 1, 2025 Completion: Nov 1, 2025
This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

Listed as NCT06421454, this NA trial focuses on Pressure Ulcer and remains actively recruiting participants. Sponsored by Fundacion Rioja Salud, it has been updated 4 times since 2024, reflecting limited change activity. This study adds to the evidence base for this therapeutic area through structured, versioned documentation.

Study Description(click to expand)

Melatonin has been shown to prevent cellular damage produced by oxidative stress or in situations of ischaemia, inhibiting the synthesis of oxidants and pro inflammatory factors such as pro-inflammatory cytokines, substances which are present in pressure ulcers and can affect the healing process, slowing it down. Melatonin gel has also been shown to prevent ulcers in the oral mucosa due to radiotherapy. Therefore, the hypothesis for this study is that the melatonin cream provides greater ulcer area reduction than standard pressure ulcer treatment. In order to o determine the efficacy of melatonin in healing pressure ulcer it has been designed a multicentre, single-blind, randomized clinical trial comparing melatonin cream as an experimental pressure ulcer treatment versus control group with standard treatment based on moist environment wound healing with a time frame of 8 weeks. In order to assess the healing rate, changes in Resvech 2.0 scale scores will be measured, as well as the ulcer surface reduction. To avoid variability in measuring ulcer surface, it will be done by using software HELCOS after taking a photograph of the wound weekly. An intention-to-treat analysis will be carried out. The t-test or Mann-Whitney will be used to check difference of means in...

Melatonin has been shown to prevent cellular damage produced by oxidative stress or in situations of ischaemia, inhibiting the synthesis of oxidants and pro inflammatory factors such as pro-inflammatory cytokines, substances which are present in pressure ulcers and can affect the healing process, slowing it down. Melatonin gel has also been shown to prevent ulcers in the oral mucosa due to radiotherapy. Therefore, the hypothesis for this study is that the melatonin cream provides greater ulcer area reduction than standard pressure ulcer treatment.

In order to o determine the efficacy of melatonin in healing pressure ulcer it has been designed a multicentre, single-blind, randomized clinical trial comparing melatonin cream as an experimental pressure ulcer treatment versus control group with standard treatment based on moist environment wound healing with a time frame of 8 weeks. In order to assess the healing rate, changes in Resvech 2.0 scale scores will be measured, as well as the ulcer surface reduction. To avoid variability in measuring ulcer surface, it will be done by using software HELCOS after taking a photograph of the wound weekly. An intention-to-treat analysis will be carried out. The t-test or Mann-Whitney will be used to check difference of means in the reduction of the area of the ulcer and variation in the Resvech 2.0 scale. Survival curves will be used to check possible differences in the follow-up time until epithelization.

Status Flow

~Jun 2024 – ~Jul 2024 · 30 days · monthly snapshot~Jul 2024 – ~Sep 2024 · 2 months · monthly snapshotNot Yet Recruiting~Sep 2024 – present · 19 months · monthly snapshotNot Yet Recruiting~Jan 2026 – present · 3 months · monthly snapshotNot Yet Recruiting

Change History

4 versions recorded
  1. Jan 2026 — Present [monthly]

    Not Yet Recruiting NA

  2. Sep 2024 — Present [monthly]

    Not Yet Recruiting NA

  3. Jul 2024 — Sep 2024 [monthly]

    Not Yet Recruiting NA

  4. Jun 2024 — Jul 2024 [monthly]

    Not Yet Recruiting NA

    First recorded

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:
  • Fundacion Rioja Salud
  • Instituto de Salud Carlos III
  • Pharmamel S.L.
  • Universidad de Granada
Data source: Fundacion Rioja Salud

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

No location information available.